[go: up one dir, main page]

MX2016009991A - Nuevo anticuerpo anti-dengue de espectro completo. - Google Patents

Nuevo anticuerpo anti-dengue de espectro completo.

Info

Publication number
MX2016009991A
MX2016009991A MX2016009991A MX2016009991A MX2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A
Authority
MX
Mexico
Prior art keywords
dengue
antibody agents
full spectrum
new anti
spectrum antibody
Prior art date
Application number
MX2016009991A
Other languages
English (en)
Other versions
MX375402B (es
Inventor
Sasisekharan Ram
Tharakaraman Kannan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2016009991A publication Critical patent/MX2016009991A/es
Publication of MX375402B publication Critical patent/MX375402B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C07K16/116—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona, entre otras cosas, agentes anticuerpos (por ejemplo, anticuerpos, y/o sus fragmentos de unión a antígeno) que se unen a epítopos del DV, así como composiciones que los contienen y método para diseñar, proporcionar, formular, usar, identificar y/o caracterizarlos. En algunas modalidades, los agentes anticuerpos provistos muestran una unión significativa a una pluralidad de serotipos del DV. En algunas modalidades, los agentes anticuerpos provistos muestran una unión significativa a los cuatro serotipos del DV. Tales agentes anticuerpos son útiles, por ejemplo, en la profilaxis, tratamiento, diagnóstico, y/o estudio del DV.
MX2016009991A 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo. MX375402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (2)

Publication Number Publication Date
MX2016009991A true MX2016009991A (es) 2016-10-07
MX375402B MX375402B (es) 2025-03-06

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009991A MX375402B (es) 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo.

Country Status (12)

Country Link
US (3) US9902764B2 (es)
EP (1) EP3104888A4 (es)
JP (1) JP6707455B2 (es)
KR (1) KR20160119806A (es)
CN (1) CN106413749B (es)
AU (1) AU2015217149B2 (es)
BR (1) BR112016017764A2 (es)
CA (1) CA2938495A1 (es)
IL (1) IL246788A0 (es)
MX (1) MX375402B (es)
SG (2) SG10201807826XA (es)
WO (1) WO2015123362A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101922788B1 (ko) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
KR20200102524A (ko) 2012-08-07 2020-08-31 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
SG11201606624WA (en) 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
DK3559027T3 (da) 2016-12-23 2022-09-05 Serum Institute Of India Pvt Ltd Fremgangsmåder til forbedring af antistofoproduktivitet i pattedyrecellekultur og minimering af aggregering nedstrøms, formuleringsprocesser og stabile antistofformuleringer opnået deraf
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
JP4579156B2 (ja) 2002-11-01 2010-11-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原組成物
WO2005056600A2 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
BRPI0614265A2 (pt) 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
ES2383191T3 (es) 2008-02-05 2012-06-19 Medical Research Council Métodos y composiciones
WO2010039154A1 (en) * 2008-10-05 2010-04-08 Board Of Trustees Of Leland Stanford Junior University Hepatitis c antibodies and uses thereof
JP5814790B2 (ja) * 2008-10-13 2015-11-17 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ デングウイルス中和抗体およびその使用
WO2010065921A2 (en) 2008-12-05 2010-06-10 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) * 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
KR20200102524A (ko) * 2012-08-07 2020-08-31 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
SG11201606624WA (en) * 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody

Also Published As

Publication number Publication date
KR20160119806A (ko) 2016-10-14
MX375402B (es) 2025-03-06
SG11201606163QA (en) 2016-08-30
WO2015123362A1 (en) 2015-08-20
IL246788A0 (en) 2016-08-31
AU2015217149A1 (en) 2016-09-08
EP3104888A4 (en) 2017-08-09
US9902764B2 (en) 2018-02-27
SG10201807826XA (en) 2018-10-30
US20200207841A1 (en) 2020-07-02
US11421018B2 (en) 2022-08-23
US20180237504A1 (en) 2018-08-23
JP6707455B2 (ja) 2020-06-10
US20150368321A1 (en) 2015-12-24
CN106413749A (zh) 2017-02-15
JP2017507131A (ja) 2017-03-16
CA2938495A1 (en) 2015-08-20
CN106413749B (zh) 2022-04-05
BR112016017764A2 (pt) 2017-10-10
AU2015217149B2 (en) 2020-09-10
EP3104888A1 (en) 2016-12-21
US10519220B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
MX2016009991A (es) Nuevo anticuerpo anti-dengue de espectro completo.
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
MX2016015398A (es) Moleculas de union tri-especificas y metodos de uso de las mismas.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
ECSP19009170A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
MX2017001597A (es) Anticuerpos anti-pd-l1.
MX2017007744A (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
CR20170079A (es) Agentes de unión a cd123 y usos de estos
MX2018002043A (es) ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
CO2017000016A2 (es) Diacuerpos heterodiméricos biespecíficos capaces de unirse en forma específica a un epítopo de p-cadherina y a un epítopo de cd3 que comprende una primera cadena polipeptídica y una segunda cadena polipeptídica y composiciones farmacéuticas de los mismos
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CR20190417A (es) Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas
AR100679A1 (es) Anticuerpos tri-específicos
MX2017013723A (es) Anticuerpo igf-ir y su uso para el diagnostico del cancer.

Legal Events

Date Code Title Description
FG Grant or registration